Benitec Biopharma Inc. financial data

Symbol
BNTC on Nasdaq
Location
Hayward, CA
Fiscal year end
30 June
Latest financial report
10-Q - Q3 2025 - 14 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2699% % 225%
Debt-to-equity 4% % -69%
Return On Equity -38% % 37%
Return On Assets -36% % 32%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 26,250,469 shares 149%
Common Stock, Shares, Outstanding 26,250,469 shares 47%
Entity Public Float $152,964,292 USD 1727%
Common Stock, Value, Issued $2,000 USD 100%
Weighted Average Number of Shares Outstanding, Basic 41,521,280 shares 49%
Weighted Average Number of Shares Outstanding, Diluted 41,521,280 shares 49%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $0 USD
Research and Development Expense $17,289,000 USD 17%
General and Administrative Expense $21,146,000 USD 177%
Operating Income (Loss) $38,435,000 USD -72%
Nonoperating Income (Expense) $3,954,000 USD 155%
Net Income (Loss) Attributable to Parent $34,481,000 USD -65%
Earnings Per Share, Basic -1 USD/shares -161%
Earnings Per Share, Diluted -1 USD/shares -161%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $94,479,000 USD 39%
Other Assets, Current $480,000 USD 13%
Assets, Current $95,079,000 USD 39%
Property, Plant and Equipment, Net $118,000 USD -23%
Operating Lease, Right-of-Use Asset $755,000 USD 270%
Other Assets, Noncurrent $20,000 USD -64%
Assets $96,027,000 USD 40%
Employee-related Liabilities, Current $463,000 USD -6.5%
Liabilities, Current $2,025,000 USD -56%
Operating Lease, Liability, Noncurrent $403,000 USD
Liabilities $2,428,000 USD -47%
Accumulated Other Comprehensive Income (Loss), Net of Tax $750,000 USD 24%
Retained Earnings (Accumulated Deficit) $237,141,000 USD -21%
Stockholders' Equity Attributable to Parent $93,599,000 USD 46%
Liabilities and Equity $96,027,000 USD 40%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $3,351,000 USD 27%
Net Cash Provided by (Used in) Financing Activities $0 USD -100%
Net Cash Provided by (Used in) Investing Activities $0 USD
Common Stock, Shares Authorized 160,000,000 shares 0%
Common Stock, Shares, Issued 26,250,469 shares 47%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $3,265,000 USD -119%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $94,592,000 USD 39%
Deferred Tax Assets, Valuation Allowance $25,044,000 USD 22%
Deferred Tax Assets, Gross $25,534,000 USD 22%
Operating Lease, Liability $817,000 USD 287%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $34,238,000 USD -63%
Lessee, Operating Lease, Liability, to be Paid $866,000 USD 303%
Property, Plant and Equipment, Gross $1,601,000 USD 1.1%
Operating Lease, Liability, Current $414,000 USD 96%
Lessee, Operating Lease, Liability, to be Paid, Year Two $291,000 USD -4%
Lessee, Operating Lease, Liability, to be Paid, Year One $100,000 USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $49,000 USD 1125%
Deferred Tax Assets, Operating Loss Carryforwards $16,473,000 USD 14%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5,000,000 shares
Operating Lease, Payments $32,000 USD -56%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $54,000 USD -42%
Share-based Payment Arrangement, Expense $22,171,000 USD 1789%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares